Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 19594743)

1.

The prenatal origins of cancer.

Marshall GM, Carter DR, Cheung BB, Liu T, Mateos MK, Meyerowitz JG, Weiss WA.

Nat Rev Cancer. 2014 Apr;14(4):277-89. doi: 10.1038/nrc3679. Epub 2014 Mar 6.

2.

AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.

Stankiewicz MJ, Crispino JD.

Leukemia. 2013 Jun;27(6):1339-47. doi: 10.1038/leu.2013.33. Epub 2013 Feb 5.

3.

Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.

Pandolfi A, Barreyro L, Steidl U.

Stem Cells Transl Med. 2013 Feb;2(2):143-50. doi: 10.5966/sctm.2012-0109. Epub 2013 Jan 24. Review.

4.

Transient Myeloproliferative Disorder and Down Syndrome: Is there a link?

Reyes ZS, Bashir W, Pathare A.

Sultan Qaboos Univ Med J. 2012 Nov;12(4):498-502. Epub 2012 Nov 20.

5.

Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells.

Chou ST, Byrska-Bishop M, Tober JM, Yao Y, Vandorn D, Opalinska JB, Mills JA, Choi JK, Speck NA, Gadue P, Hardison RC, Nemiroff RL, French DL, Weiss MJ.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17573-8. doi: 10.1073/pnas.1211175109. Epub 2012 Oct 8.

6.

Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells.

Maclean GA, Menne TF, Guo G, Sanchez DJ, Park IH, Daley GQ, Orkin SH.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17567-72. doi: 10.1073/pnas.1215468109. Epub 2012 Oct 8.

7.

Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.

Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, Gu├ęgan J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Reinhardt D, Bornhauser B, Gautheret D, Lecluse Y, Landman-Parker J, Radford I, Vainchenker W, Dastugue N, de Botton S, Dessen P, Bourquin JP, Crispino JD, Ballerini P, Bernard OA, Pflumio F, Mercher T.

J Exp Med. 2012 Oct 22;209(11):2017-31. doi: 10.1084/jem.20121343. Epub 2012 Oct 8.

8.

Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia.

Carmichael CL, Metcalf D, Henley KJ, Kruse EA, Di Rago L, Mifsud S, Alexander WS, Kile BT.

Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15437-42. Epub 2012 Aug 30.

9.

Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment.

Fowler TW, McKelvey KD, Akel NS, Vander Schilden J, Bacon AW, Bracey JW, Sowder T, Skinner RA, Swain FL, Hogue WR, Leblanc DB, Gaddy D, Wenger GR, Suva LJ.

PLoS One. 2012;7(8):e42967. doi: 10.1371/journal.pone.0042967. Epub 2012 Aug 14.

10.

N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.

Kaneko H, Kobayashi E, Yamamoto M, Shimizu R.

J Biol Chem. 2012 Jun 15;287(25):21439-49. doi: 10.1074/jbc.M112.370437. Epub 2012 May 2.

11.

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD.

J Clin Invest. 2012 Mar;122(3):948-62. doi: 10.1172/JCI60455. Epub 2012 Feb 22.

12.

Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia.

Perluigi M, Butterfield DA.

Curr Gerontol Geriatr Res. 2012;2012:724904. doi: 10.1155/2012/724904. Epub 2011 Nov 29.

13.

Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report.

Tragiannidis A, Pana ZD, Papageorgiou T, Hatzipantelis E, Hatzistilianou M, Athanassiadou F.

J Med Case Rep. 2011 Aug 24;5:407. doi: 10.1186/1752-1947-5-407.

14.

GATA Transcription Factors and Cancer.

Zheng R, Blobel GA.

Genes Cancer. 2010 Dec;1(12):1178-88. doi: 10.1177/1947601911404223.

15.

Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.

Inaba H, Londero M, Maurer SH, Onciu M, Ge Y, Taub JW, Rubnitz JE, Raimondi SC.

J Clin Oncol. 2011 Mar 20;29(9):e230-3. doi: 10.1200/JCO.2010.32.3634. Epub 2011 Jan 4. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk